Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.

@article{MirakiMoud2015ArginineDU,
  title={Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.},
  author={Farideh Miraki-Moud and Essam Ghazaly and Linda Ariza-McNaughton and Katharine A Hodby and Andrew Clear and Fernando Anjos-Afonso and Konstantinos S Liapis and Marianne Grantham and Fareeda Sohrabi and Jamie D. Cavenagh and John Stephen Bomalaski and John G Gribben and Peter Wojciech Szlosarek and Dominique Bonnet and David Christopher Taussig},
  journal={Blood},
  year={2015},
  volume={125 26},
  pages={4060-8}
}
The strategy of enzymatic degradation of amino acids to deprive malignant cells of important nutrients is an established component of induction therapy of acute lymphoblastic leukemia. Here we show that acute myeloid leukemia (AML) cells from most patients with AML are deficient in a critical enzyme required for arginine synthesis, argininosuccinate synthetase-1 (ASS1). Thus, these ASS1-deficient AML cells are dependent on importing extracellular arginine. We therefore investigated the effect… CONTINUE READING
20 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Randomized trial of arginine deprivation with pegylated arginine deiminase in patients with malignant pleural mesothelioma [abstract

  • PW Szlosarek, JP Steele, L Nolan
  • J Clin Oncol
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…